Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China.

Front Oncol · 2026 · PMC13381218 · PMID 42518819

Europe PMC DOI

hedged sentence

0.0720

closest p · 1.4× alpha

0.0720

boldest claim

The sentences

a strong trendp = 0.072so close (0.05 < p ≤ 0.1)

Furthermore, among advanced-stage patients, the sufficient-dose A-AVD group showed a strong trend toward improved PFS compared with the ABVD cohort (2-year PFS 91.7% vs. 65.8%; log-rank p = 0.072; Figure 2E ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.